This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

TheDeal: Valeant Surges on $8.7 Billion Bausch & Lomb Acquisition

Stocks in this article: VRX

NEW YORK ( TheDeal) -- Valeant Pharmaceuticals International (VRX) is surging Tuesday following its announced deal to acquire Bausch & Lomb Inc. from Warburg Pincus LLC for $8.7 billion, as the Canadian pharmaceutical company moves to capitalize on the ever-increasing demand for contact lenses and other eye health products.

Terms of the deal, formally announced on Monday, May 27, call for Laval, Quebec-based Valeant to pay $4.5 billion to an investor group led by Warburg Pincus, with the remaining $4.2 billion in cash to be used to repay Bausch & Lomb's outstanding debt.

Valeant was gaining 7.8% to $91.03 in mid-day trading.

Warburg bought the company in October 2007 for $4.5 billion in cash and assumed debt, and has extracted about $800 million out of Bausch in the years since.

Rochester, N.Y.-based Bausch makes contact lenses, solutions, optic surgical equipment and pharmaceuticals. The company is expected to generate Ebitda of $720 million on sales of $3.3 billion in 2013, and Valeant said it expects to be able to extract at least $800 million in annual cost savings by the end of 2014.

The deal will be financed with debt and upward of $2 billion of new equity. Valeant said it has secured fully committed debt financing for the transaction from Goldman Sachs Bank USA.

Post-deal Valeant's ophthalmology business will be folded into the company's new Bausch + Lomb division, creating an eye health unit with more than $3.5 billion in annual sales. Valeant said it expects to capitalize in future years on an expected surge in eye health needs driven by an aging patient population, an increase in diabetes rates and higher demand from emerging markets.

"Bausch & Lomb's world-renowned brand, comprehensive portfolio of leading eye care products, and promising late stage pipeline are an ideal strategic fit for our current ophthalmology business and we are strongly committed to continuing to build a sustainable eye health business," Valeant chairman and CEO J. Michael Pearson said in a statement. "With this transaction, Valeant will be a worldwide leader in both dermatology and eye health."

A Skadden, Arps, Slate, Meagher & Flom LLP team led by Stephen Arcano, Marie Gibson and Jeffrey Brill is joining Osler, Hoskin & Harcourt LLP in advising Valeant. Bausch/&/Lomb was advised by attorneys with Cleary Gottlieb Steen & Hamilton LLP, with Goldman, Sachs & Co. and JPMorgan Securities LLC acting as financial advisers.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,959.44 +154.64 0.87%
S&P 500 2,078.54 +7.89 0.38%
NASDAQ 4,781.4240 +16.0440 0.34%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs